Home > News > Analyzing nanoparticle levels in blood
May 22nd, 2007
Analyzing nanoparticle levels in blood
Abstract:
With the race to develop nanoparticle-based therapeutics and imaging agents for cancer applications moving at full speed, a small but growing group of researchers is quietly developing the methods that are needed to fully characterize a wide variety of nanoscale materials and then detect and quantify their presence in blood and other human tissues. One such effort, headed by King Chan, Ph.D., of the National Cancer Institute, and Anil Patri, Ph.D., of the Nanotechnology Characterization Laboratory, has now developed a straightforward method for analyzing two types of fullerene nanoparticle.
Source:
nanowerk.com
Bookmark:
| Related News Press |
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
UC Irvine physicists discover method to reverse ‘quantum scrambling’ : The work addresses the problem of information loss in quantum computing system April 17th, 2026
Safety-Nanoparticles/Risk management
Tiny nanosheets, big leap: A new sensor detects ethanol at ultra-low levels January 30th, 2026
Onion-like nanoparticles found in aircraft exhaust May 14th, 2025
Closing the gaps — MXene-coating filters can enhance performance and reusability February 28th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||